BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo

Reuters11-14

Nov 14 (Reuters) - EMA's CHMP:

EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR KOSELUGO
EMA'S CHMP: RECOMMENDS MARKETING AUTHORISATION FOR DAWNZERA - WEBSITE
EMA'S CHMP: INLURIYO RECEIVES POSITIVE OPINION
EMA'S CHMP: ADOPTED POSITIVE OPINION FOR WASKYRA (ETUVETIDIGENE AUTOTEMCEL), FIRST GENE THERAPY TO TREAT WISKOTT-ALDRICH SYNDROME
EMA'S CHMP: ADOPTS POSITIVE OPINION FOR TEIZEILD
EMA'S CHMP: APPLICATION FOR OHTUVAYRE WITHDRAWN
EMA'S CHMP: APPLICATION FOR NURZIGMA WITHDRAWN
EMA'S CHMP: TEDUGLUTIDE RECEIVES POSITIVE OPINION

Source text: [ID:]

Further company coverage: AZN.L

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583508690?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583508690","market":"fut","top_or_hot":-1,"title":"BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo</title></head><body><p><span>Nov 14 (Reuters)</span><span> - </span>EMA's CHMP: </p><ul><li><p>EMA'S CHMP:  POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR KOSELUGO</p></li><li><p>EMA'S CHMP: RECOMMENDS MARKETING AUTHORISATION FOR DAWNZERA - WEBSITE</p></li><li><p>EMA'S CHMP: INLURIYO RECEIVES POSITIVE OPINION</p></li><li><p>EMA'S CHMP:  ADOPTED POSITIVE OPINION FOR WASKYRA (ETUVETIDIGENE AUTOTEMCEL), FIRST GENE THERAPY TO TREAT WISKOTT-ALDRICH SYNDROME</p></li><li><p>EMA'S CHMP: ADOPTS POSITIVE OPINION FOR TEIZEILD</p></li><li><p>EMA'S CHMP: APPLICATION FOR OHTUVAYRE WITHDRAWN</p></li><li><p>EMA'S CHMP: APPLICATION FOR NURZIGMA WITHDRAWN</p></li><li><p>EMA'S CHMP: TEDUGLUTIDE RECEIVES POSITIVE OPINION</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>AZN.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo</title></head><body><p><span>Nov 14 (Reuters)</span><span> - </span>EMA's CHMP: </p><ul><li><p>EMA'S CHMP:  POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR KOSELUGO</p></li><li><p>EMA'S CHMP: RECOMMENDS MARKETING AUTHORISATION FOR DAWNZERA - WEBSITE</p></li><li><p>EMA'S CHMP: INLURIYO RECEIVES POSITIVE OPINION</p></li><li><p>EMA'S CHMP:  ADOPTED POSITIVE OPINION FOR WASKYRA (ETUVETIDIGENE AUTOTEMCEL), FIRST GENE THERAPY TO TREAT WISKOTT-ALDRICH SYNDROME</p></li><li><p>EMA'S CHMP: ADOPTS POSITIVE OPINION FOR TEIZEILD</p></li><li><p>EMA'S CHMP: APPLICATION FOR OHTUVAYRE WITHDRAWN</p></li><li><p>EMA'S CHMP: APPLICATION FOR NURZIGMA WITHDRAWN</p></li><li><p>EMA'S CHMP: TEDUGLUTIDE RECEIVES POSITIVE OPINION</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>AZN.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0353189763.USD","symbol_name":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ104:1","article_id":"2583508690","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583508690","pubTimestamp":1763120862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For KoselugoNov 14  - EMA's CHMP: EMA'S CHMP:  POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR KOSELUGOEMA'S CHMP: RECOMMENDS MARKETING AUTHORISATION FOR DAWNZERA - WEBSITEEMA'S CHMP: INLURIYO RECEIVES POSITIVE OPINIONEMA'S CHMP:  ADOPTED POSITIVE OPINION FOR WASKYRA , FIRST GENE THERAPY TO TREAT WISKOTT-ALDRICH SYNDROMEEMA'S CHMP: ADOPTS POSITIVE OPINION FOR TEIZEILDEMA'S CHMP: APPLICATION FOR OHTUVAYRE WITHDRAWNEMA'S CHMP: APPLICATION FOR NURZIGMA WITHDRAWNEMA'S CHMP: TEDUGLUTIDE RECEIVES POSITIVE OPINIONSource text: [ID:]Further company coverage: AZN.L ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","03165":"华夏欧优股对冲","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0499090636.EUR":"AZ FUND 1 DIVIDEND PREMIUM \"A-AZ\" ACC","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0823399737.USD":"BNP PARIBAS EUROPE EQUITY \"C\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","LU0969580561.USD":"贝莱德欧洲特别时机基金A2","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","VTRS":"Viatris Inc.","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0171293334.USD":"贝莱德英国基金A2","AZN.UK":"阿斯利康制药"},"translate_title":"简报-EMA的CHMP宣布关于延长Koselugo治疗适应症的积极建议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"VTRS":0.9,"AZN.UK":0.9},"content_text":"BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For KoselugoNov 14 (Reuters) - EMA's CHMP: EMA'S CHMP:  POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR KOSELUGOEMA'S CHMP: RECOMMENDS MARKETING AUTHORISATION FOR DAWNZERA - WEBSITEEMA'S CHMP: INLURIYO RECEIVES POSITIVE OPINIONEMA'S CHMP:  ADOPTED POSITIVE OPINION FOR WASKYRA (ETUVETIDIGENE AUTOTEMCEL), FIRST GENE THERAPY TO TREAT WISKOTT-ALDRICH SYNDROMEEMA'S CHMP: ADOPTS POSITIVE OPINION FOR TEIZEILDEMA'S CHMP: APPLICATION FOR OHTUVAYRE WITHDRAWNEMA'S CHMP: APPLICATION FOR NURZIGMA WITHDRAWNEMA'S CHMP: TEDUGLUTIDE RECEIVES POSITIVE OPINIONSource text: [ID:]Further company coverage: AZN.L ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583508690","isCrawlerRequest":true}